6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine] hydrochloride | 1017600-77-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine] hydrochloride
• 英文别名: 6-Fluoro-1h-spiro[furo[3,4-c]pyridine-3,4'-piperidine]hydrochloride；6-fluorospiro[1H-furo[3,4-c]pyridine-3,4'-piperidine];hydrochloride
• CAS: 1017600-77-9
• 化学式: C₁₁H₁₃FN₂O*ClH
• 分子量: 244.696
• InChiKey: BGDVCEMCEMTUMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.75
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  34.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine] hydrochloride 、 4-(3,4-二氟苯氧基)苯甲醛 在 Zn(BH3CN)2 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 17.0h， 以86%的产率得到1'-[[4-(3,4-difluorophenoxy)phenyl]methyl]-6-fluorospiro[1H-furo[3,4-c]pyridine-3,4'-piperidine]
  参考文献：
  名称：

  发现新型二芳基酮肟衍生物作为选择性和口服活性黑色素浓缩激素1受体拮抗剂

  摘要：

  铅2a的优化导致鉴定了一种新型的二芳基酮肟类黑色素浓缩激素1受体（MCH-1R）拮抗剂。我们的重点是提高hERG活性和代谢稳定性。代表性的衍生物4b在口服给药后，在饮食诱导的肥胖（DIO）C57BL / 6J小鼠中显示出有效且剂量依赖性的体重降低。描述了新型二芳基酮肟MCH-1R拮抗剂的合成及其构效关系。

  DOI：

  10.1016/j.bmcl.2009.07.132
• 作为产物：
  描述：

  1'-benzylspiro[4-chloro-5-fluoro-6-azaisobenzofuran-1(3H)-4'-piperidine] 在 palladium(II) hydroxide/carbon 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 生成 6-fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine] hydrochloride
  参考文献：
  名称：

  EP2072519

  摘要：

  公开号：

文献信息

• DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：EP2272841A1

  公开（公告）日：2011-01-12

  [Problem] To provide a melanin-concentrating hormone receptor antagonist useful as a pharmaceutical agent for central diseases, circulatory diseases, and metabolic diseases. [Means for Resolution] Provided is a diarylmethylamide derivative represented by formula (I): Wherein R1a, R1b, R2a, R2b, R3a, and R3b independently represent a hydrogen atom or the like, R4 represents a hydrogen atom, C1-6 alkyl, or the like, R5 represents a hydrogen atom or the like, Z represents C1-6 alkyl or the like, or R4 and Z together form a 4- to 6-membered nitrogen-containing hetero ring, Y1 represents H or the like, Y2 represents H, or Y1 and Y2 together form - O-CH2-, W represents C, SO, or the like, Ar1 represents 6-membered aryl or the like, Ar2 represents 6-membered aryl or the like, and ring A represents a benzene ring, a pyridine ring, or the like.

  [问题] 提供一种对黑色素浓缩激素受体拮抗剂，用作中枢疾病、循环疾病和代谢疾病的药用制剂。 [解决方法] 提供一种由式(I)表示的二芳基甲酰胺衍生物： 其中R1a、R1b、R2a、R2b、R3a和R3b独立地表示氢原子或类似物，R4表示氢原子、C1-6烷基或类似物，R5表示氢原子或类似物，Z表示C1-6烷基或类似物，或者R4和Z一起形成一个含氮杂环的4-至6-成员环，Y1表示H或类似物，Y2表示H，或者Y1和Y2一起形成-O-CH2-，W表示C、SO或类似物，Ar1表示6-成员芳基或类似物，Ar2表示6-成员芳基或类似物，环A表示苯环、吡啶环或类似物。
• Diaryl ketimine derivative
  申请人：Ando Makoto

  公开号：US20090247560A1

  公开（公告）日：2009-10-01

  Provided is a compound of a formula (I): [wherein R 1a and R 1b are the same or different, representing a hydrogen atom, etc.; R 2a and R 2b are the same or different, representing a hydrogen atom, etc., or R 2a and R 2b , taken together, form —CH 2 CH 2 —, R 3a and R 3b are the same or different, representing a hydrogen atom, etc.; or R 3a and R 3b , taken together, form —CH 2 CH 2 -etc.; Y 1 and Y 2 represent —C(R) 2 —, etc.; Z represents OR, NR 2 , etc.; R represents a hydrogen atom, a C 1-6 alkyl group, etc.; Ar 1 represents a 6-membered aromatic carbocyclic group, etc.; Ar 2 represents a 6-membered aromatic carbocyclic group, etc; A 3 represents a 6-membered aromatic carbocyclic group etc.]. The compound is useful as a medicine for central disorders, cardiovascular disorders, metabolic disorders.

  提供的是化合物公式(I)的复合物：[其中R1a和R1b相同或不同，代表氢原子等；R2a和R2b相同或不同，代表氢原子等，或者R2a和R2b结合形成-CH2CH2-，R3a和R3b相同或不同，代表氢原子等；或者R3a和R3b结合形成-CH2CH2-等；Y1和Y2代表-C(R)2-等；Z代表OR、NR2等；R代表氢原子、C1-6烷基等；Ar1代表6-成员芳香环烷基等；Ar2代表6-成员芳香环烷基等；A3代表6-成员芳香环烷基等。]该化合物可用作治疗中枢障碍、心血管障碍、代谢障碍的药物。
• DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM
  申请人：Kamijo Kaori

  公开号：US20110015198A1

  公开（公告）日：2011-01-20

  [Problem] To provide a melanin-concentrating hormone receptor antagonist useful as a pharmaceutical agent for central diseases, circulatory diseases, and metabolic diseases. [Means for Resolution] Provided is a diarylmethylamide derivative represented by formula (I): Wherein R 1a , R 1b , R 2a , R 2b , R 3a , and R 3b independently represent a hydrogen atom or the like, R 4 represents a hydrogen atom, C 1-6 alkyl, or the like, R 5 represents a hydrogen atom or the like, Z represents C 1-6 alkyl or the like, or R 4 and Z together form a 4- to 6-membered nitrogen-containing hetero ring, Y 1 represents H or the like, Y 2 represents H, or Y 1 and Y 2 together form —O—CH 2 —, W represents C, SO, or the like, Ar 1 represents 6-membered aryl or the like, Ar 2 represents 6-membered aryl or the like, and ring A represents a benzene ring, a pyridine ring, or the like.

  [问题] 提供一种黑色素浓缩激素受体拮抗剂，用作中枢疾病、循环系统疾病和代谢疾病的药物。 [解决方法] 提供了一种日萘基甲酰胺衍生物，其表示为式（I）：其中，R1a、R1b、R2a、R2b、R3a和R3b独立地表示氢原子或类似物，R4表示氢原子、C1-6烷基或类似物，R5表示氢原子或类似物，Z表示C1-6烷基或类似物，或者R4和Z共同形成一个含有氮的4-6元杂环，Y1表示H或类似物，Y2表示H，或者Y1和Y2共同形成-O-CH2-，W表示C、SO或类似物，Ar1表示6元芳基或类似物，Ar2表示6元芳基或类似物，环A表示苯环、吡啶环或类似物。
• DIARYL KETIMINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP2072519A1

  公开（公告）日：2009-06-24

  Provided is a compound of a formula (I): [wherein R1a and R1b are the same or different, representing a hydrogen atom, etc.; R2a and R2b are the same or different, representing a hydrogen atom, etc., or R2a and R2b, taken together, form -CH2CH2-, R3a and R3b are the same or different, representing a hydrogen atom, etc.; or R3a and R3b, taken together, form - CH2CH2-etc.; Y1 and Y2 represent -C(R)2-, etc.; Z represents OR, NR2, etc.; R represents a hydrogen atom, a C1-6 alkyl group, etc.; Ar1 represents a 6-membered aromatic carbocyclic group, etc.; Ar2 represents a 6-membered aromatic carbocyclic group, etc; A3 represents a 6-membered aromatic carbocyclic group etc.]. The compound is useful as a medicine for central disorders, cardiovascular disorders, metabolic disorders.

  本文提供了一种式 (I) 的化合物： [其中 R1a 和 R1b 相同或不同，代表氢原子等；R2a 和 R2b 相同或不同，代表氢原子等、或 R2a 和 R2b 相同或不同，代表氢原子等；或 R3a 和 R3b 相同或不同，代表-CH2CH2-等； Y1 和 Y2 代表-C(R)2-等； Z 代表 OR、NR2 等。R 代表氢原子、C1-6 烷基等；Ar1 代表 6 元芳香碳环基团等；Ar2 代表 6 元芳香碳环基团等；A3 代表 6 元芳香碳环基团等]。该化合物可作为治疗中枢性疾病、心血管疾病和代谢紊乱的药物。
• Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists
  作者：Takao Suzuki、Minoru Kameda、Makoto Ando、Hiroshi Miyazoe、Etsuko Sekino、Satoru Ito、Kouta Masutani、Kaori Kamijo、Akihiro Takezawa、Minoru Moriya、Masahiko Ito、Junko Ito、Kazuho Nakase、Hiroko Matsushita、Akane Ishihara、Norihiro Takenaga、Shigeru Tokita、Akio Kanatani、Nagaaki Sato、Takehiro Fukami

  DOI：10.1016/j.bmcl.2009.07.132

  日期：2009.9

  Optimization of the lead 2a led to the identification of a novel diarylketoxime class of melanin-concentrating hormone 1 receptor (MCH-1R) antagonists. Our focus was directed toward improvement of hERG activity and metabolic stability. The representative derivative 4b showed potent and dose-dependent body weight reduction in diet-induced obese (DIO) C57BL/6J mice after oral administration. The synthesis

  铅2a的优化导致鉴定了一种新型的二芳基酮肟类黑色素浓缩激素1受体（MCH-1R）拮抗剂。我们的重点是提高hERG活性和代谢稳定性。代表性的衍生物4b在口服给药后，在饮食诱导的肥胖（DIO）C57BL / 6J小鼠中显示出有效且剂量依赖性的体重降低。描述了新型二芳基酮肟MCH-1R拮抗剂的合成及其构效关系。